U.S. Markets closed

AMAG Pharmaceuticals, Inc. (AMAG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.23+0.30 (+3.36%)
At close: 4:00PM EDT

9.23 0.00 (0.00%)
After hours: 4:03PM EDT

Full screen
Loading interactive chart...
  • GlobeNewswire

    AMAG Pharmaceuticals to Participate in H.C. Wainwright 22nd Annual Global Investment Conference

    WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Scott Myers, Chief Executive Officer, and Brian Piekos, Chief Financial Officer, will participate in a fireside chat at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 10:30 a.m. Eastern Time. A live audio webcast of the virtual event will be accessible through the Investors section of the company’s website at www.amagpharma.com. A replay of the webcast will be archived on the company’s website for 30 days.About AMAGAMAG is a commercial stage biopharmaceutical company focused on bringing innovative products to patients with unmet medical needs. The company does this by leveraging its development and commercial expertise to invest in and grow its pharmaceutical products across a range of therapeutic areas. For additional company information, please visit www.amagpharma.com.AMAG Pharmaceuticals®, the logo and designs, are registered trademarks of AMAG Pharmaceuticals, Inc.AMAG Pharmaceuticals Contact: Loraine Spreen 617-866-0303

  • AMAG Pharmaceuticals (AMAG) Down 0.4% Since Last Earnings Report: Can It Rebound?
    Zacks

    AMAG Pharmaceuticals (AMAG) Down 0.4% Since Last Earnings Report: Can It Rebound?

    AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • AMAG Pharmaceuticals (AMAG) Moves to Buy: Rationale Behind the Upgrade
    Zacks

    AMAG Pharmaceuticals (AMAG) Moves to Buy: Rationale Behind the Upgrade

    AMAG Pharmaceuticals (AMAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).